The price a stock trades at can drastically impact your overall returns. If you wait for a top growth stock to come down to a ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December scripts boost. The stock is attractively valued at current levels.

GLP-1 drugs have become all the rage for weight loss, with sales for drugs like Novo Nordisk's Ozempic and Eli Lilly's (NYSE: LLY) Mounjaro skyrocketing over the past year. However, Eli Lilly ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

GLP-1 drugs have become all the rage for weight loss, with sales for drugs like Novo Nordisk's Ozempic and Eli ... drug portfolio is also growing nicely. From a valuation perspective, Lilly ...

With its 2-star rating, we believe Eli Lilly’s stock is over-valued compared to ... with the largest drug, Trulicity, representing almost 25% of total sales, which sets up manageable cash ...

Eli Lilly and Company (NYSE: LLY) is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the ...

On Friday, Novo Nordisk released promising trial results for its obesity treatment, amycretin, which showed a significant weight loss in participants, outpacing Eli Lilly's own drug in early ...

We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump’s Sovereign Wealth Fund. In this ...